Through in vitro experiments, they revealed the same strengths and weaknesses of this drug as was found in breast cancer: PD0332991 inhibited cell proliferation in Rb1 proficient glioblastoma cells and Rb1 deficiency caused resistance (31). This evidence concerns the gene RB1 and breast carcinoma.